1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aida Pharmaceuticals, Inc.

Aida Pharmaceuticals, Inc.

AIDA
Aida Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
8,101.00Market Cap
Aida Pharmaceuticals, Inc.
AIDA
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
TTM
FRC
1.04
1.14
1.08
1.52
Revenue per Share
0.06
0.06
0.1
-0.08
Basic EPS, GAAP
0.23
-0.01
0.18
0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
0.14
0.18
0.27
0.1
Book Value per Share
0.29
0.23
0.45
-0.1
Tangible Book Value per Share
23
26
27
27
Basic Weighted Avg Shares
25
30
29
41
Sales/Revenue/Turnover
8.64
13.28
18.65
- -
Operating Margin (%)
2
2
2
2
Depreciation Expense
1
1
3
-2
Net Income, GAAP
9.59
7.46
17.81
55.17
Effective Tax Rate (%)
5.99
4.9
9.38
-5.11
Profit Margin (%)
-6
-1
-3
-12
Working Capital
4
6
2
9
LT Debt
10
15
21
17
Total Equity
- -
9.03
8.96
9.26
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
36.78
45.76
-54.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
ST Debt
30
29
33
LT Borrowings
7
7
9
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
31
22
13

Working Capital

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
Total Current Assets
41
26
32
Cash, Cash Equivalents & STI
16
6
10
Accounts Receivable, Net
10
11
10
Inventories
4
4
5
Total Current Liabilities
38
40
44
Payables & Accruals
3
3
3
ST Debt
30
29
33
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
37.34%
Free Cash Flow
- -
- -
-1,652.6%
Net Income, GAAP
- -
- -
88.49%
Sales/Revenue/Turnover
- -
- -
-1.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
5
7
7
10
30
2007
5
6
7
11
29
2008
8
11
12
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
0.02
0.04
- -
0.06
2007
-0.01
- -
0.02
- -
0.1
2008
- -
-0.25
0.08
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
Similar Companies
NutraLife BioSciences, Inc. (NLBS)
Catalent, Inc. (CTLT)
Alembic Pharmaceuticals Limited (APLLTD.NS)
Shandong Xinhua Pharmaceutical Company Limited (0719.HK)
XPhyto Therapeutics Corp. (4XT.DE)
StateHouse Holdings Inc. (STHZ.CN)
Business
Aida Pharmaceuticals, Inc. Aida Pharmaceuticals, Inc. (AIDA), together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products primarily in mainland China. The company offers antibiotics including Etimicin Sulfate in injectable powder form for treating respiratory, kidney, urinogenital, soft skin tissue infections, and preventive uses in trauma and operations; cardiovascular drugs; and anti-cancer therapies such as rh-Apo2l, a biopharmaceutical recombinant human Apo2L/TNF-related apoptosis-inducing ligand; with products provided in powder for injection, liquid for intravenous injection, capsules, tablets, and ointments. Founded in 1999 and headquartered at 31 Dingjiang Road, Jianggan District, Hangzhou, China, Aida Pharmaceuticals, Inc. operates in the healthcare sector's drug manufacturers - specialty and generic industry, employing approximately 450 people under Chairman and CEO Biao Jin, with key subsidiaries including Hangzhou Aida Pharmaceutical Co., Ltd. and Changzhou Fangyuan Pharmaceutical Co., Ltd.. No major recent changes such as partnerships, acquisitions, funding rounds, new product launches, or strategic expansions within the last 1-2 years are reported in available public sources.